Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab
Sign Up to like & getrecommendations! Published in 2022 at "Liver International"
DOI: 10.1111/liv.15487
Abstract: The combination of atezolizumab and bevacizumab (AtezoBev) is the current first‐line treatment for patients with hepatocellular carcinoma (HCC). Our aim was to evaluate the prognostic role of alpha‐foetoprotein (AFP) early response and its combination with… read more here.
Keywords: baseline albi; early variation; score early; atezolizumab bevacizumab ... See more keywords